title: [Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
abstract: OBJECTIVE
  To explore the clinical efficiency and safety of CHOP regimen containing pegylated liposomal doxorubicin (PLD) for the aged patients with advanced diffuse large B-cell lymphoma (DLBCL).
  
  
  METHODS
  Fifty aged patients with advanced DLBCL treated in our hospital from February 2010 to February 2014 were selected and divided into two groups. Out of 50 cases, 25 cases received standard CHOP regimen (sCHOP group), other 25 cases received CHOP regimen containing PLD at dose of 30 mg/m2 (PLD+CHOP). These patients were followed up for 18 months, and the total effective rate, the survival rate and the adverse reaction rate were compared between these two groups.
  
  
  RESULTS
  After receiving different treatments, the survival rate of patients on 6, 12 and 18 months in PLD+CHOP group was 88.0%, 80.0% and 76.0%, respectively, and the survival rate of 18 month was significantly higher than that in the sCHOP group (P<0.05); The total effective rate in the PLD+CHOP group was statistically higher than that in the sCHOP group (P<0.05); and all the incidences of non-hematological toxicity, peripheral sensory neuropathy, lung infection, gastrointestinal reaction and hepatotoxicity were not statistically different between two groups (P>0.05), while the incidence of cardiac toxicity including acute myocardial infarction, congestive heart failure, atrioventricular block (AV block) and paroxysmal atrial tachycardia significantly decreased in the PLD+CHOP group (P<0.05).
  
  
  CONCLUSIONS
  The efficiency of CHOP regimen containing PLD for the aged patients with advanced DLBCL has been confirmed to be significant, and its cardiac toxicity is low, thus being worth to be popularized and applied for the treatment of advanced diffuse large B-cell lymphoma.
authors.affiliation: Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China. E-mail: zhihui060982@163.com.
authors.forename: Zhi-Hui
authors.initials: ZH
authors.lastname: Li
authors.affiliation: Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.
authors.forename: Ming-Tao
authors.initials: MT
authors.lastname: Xing
authors.affiliation: Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.
authors.forename: Yan-Pin
authors.initials: YP
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Hematology, Xinxiang Municipal Central Hospital, Xinxiang 453000, Henan Province, China.
authors.forename: Xin-Rong
authors.initials: XR
authors.lastname: Zhan
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
chemical_list: C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone